These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 36091003)

  • 21. Efficacy and safety of apatinib and transcatheter arterial chemoembolization as second-line therapy for advanced hepatocellular carcinoma: A retrospective cohort study.
    Li T; Zhao J; Zhang S; Wang H; Sun L; Hu J
    J Cancer Res Ther; 2023 Feb; 19(1):57-63. PubMed ID: 37006043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial.
    Liu J; Liu Q; Li Y; Li Q; Su F; Yao H; Su S; Wang Q; Jin L; Wang Y; Lau WY; Jiang Z; Song E
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32448804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study.
    Zhang Y; Song L; Zeng L; Xiong Y; Liu L; Zhou C; Yang H; Wang Z; Xia Q; Jiang W; Xu Q; Yang N
    BMC Cancer; 2022 Sep; 22(1):952. PubMed ID: 36064386
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
    Diéras V; Miles D; Verma S; Pegram M; Welslau M; Baselga J; Krop IE; Blackwell K; Hoersch S; Xu J; Green M; Gianni L
    Lancet Oncol; 2017 Jun; 18(6):732-742. PubMed ID: 28526536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TACE with dicycloplatin in patients with unresectable hepatocellular carcinoma: a multicenter randomized phase II trial.
    Zhu HD; Li X; Ji JS; Huang M; Shao GL; Lu J; Zhao XY; Li HL; Yang ZQ; Tu JF; Zhou JM; Zeng CH; Teng GJ
    Eur Radiol; 2022 Nov; 32(11):7335-7343. PubMed ID: 35776182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3).
    Shi Y; Wu L; Yu X; Xing P; Wang Y; Zhou J; Wang A; Shi J; Hu Y; Wang Z; An G; Fang Y; Sun S; Zhou C; Wang C; Ye F; Li X; Wang J; Wang M; Liu Y; Zhao Y; Yuan Y; Feng J; Chen Z; Shi J; Sun T; Wu G; Shu Y; Guo Q; Zhang Y; Song Y; Zhang S; Chen Y; Li W; Niu H; Hu W; Wang L; Huang J; Zhang Y; Cheng Y; Wu Z; Peng B; Sun J; Mancao C; Wang Y; Sun L
    Cancer Commun (Lond); 2022 Dec; 42(12):1314-1330. PubMed ID: 36336841
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial.
    Mei K; Qin S; Chen Z; Liu Y; Wang L; Zou J
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741732
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Apatinib Plus Toripalimab (Anti-PD1 Therapy) as Second-Line Therapy in Patients With Advanced Gastric or Esophagogastric Junction Cancer: Results From a Randomized, Open-Label Phase II Study.
    Wei Q; Xu X; Li J; Wang C; Chen W; Xie Y; Luo C; Chen L; Chu J; Wu W; Han Z; Yang Y; Hu Z; Xu Q; Ying J
    Oncologist; 2024 Apr; 29(4):364-e578. PubMed ID: 38366886
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sintilimab plus Lenvatinib conversion therapy for intermediate/locally advanced hepatocellular carcinoma: A phase 2 study.
    Wang L; Wang H; Cui Y; Liu M; Jin K; Xu D; Wang K; Xing B
    Front Oncol; 2023; 13():1115109. PubMed ID: 36874115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Apatinib as first-line treatment in patients with advanced hepatocellular carcinoma: a phase II clinical trial.
    Hou Z; Zhu K; Yang X; Chen P; Zhang W; Cui Y; Zhu X; Song T; Li Q; Li H; Zhang T
    Ann Transl Med; 2020 Sep; 8(17):1047. PubMed ID: 33145266
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study.
    Xu J; Zhang Y; Jia R; Yue C; Chang L; Liu R; Zhang G; Zhao C; Zhang Y; Chen C; Wang Y; Yi X; Hu Z; Zou J; Wang Q
    Clin Cancer Res; 2019 Jan; 25(2):515-523. PubMed ID: 30348638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).
    Zhang Z; Luo F; Zhang Y; Ma Y; Hong S; Yang Y; Fang W; Huang Y; Zhang L; Zhao H
    Cancer Commun (Lond); 2019 Nov; 39(1):69. PubMed ID: 31699150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy: an open-label phase 2 study.
    Lu N; Jiang YF; Xia WX; Huang Y; Xie CM; Xu C; Ye YF; Liu GY; Bei WX; Ke LR; Li WZ; Zhang C; Wang X; Liu Q; Chen X; Chen ZX; Xie C; Liang H; Xiang YQ
    EClinicalMedicine; 2023 Aug; 62():102136. PubMed ID: 37593221
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
    Qin S; Li Q; Gu S; Chen X; Lin L; Wang Z; Xu A; Chen X; Zhou C; Ren Z; Yang L; Xu L; Bai Y; Chen L; Li J; Pan H; Cao B; Fang W; Wu W; Wang G; Cheng Y; Yu Z; Zhu X; Jiang D; Lu Y; Wang H; Xu J; Bai L; Liu Y; Lin H; Wu C; Zhang Y; Yan P; Jin C; Zou J
    Lancet Gastroenterol Hepatol; 2021 Jul; 6(7):559-568. PubMed ID: 33971141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study.
    Chen X; Li W; Wu X; Zhao F; Wang D; Wu H; Gu Y; Li X; Qian X; Hu J; Li C; Xia Y; Rao J; Dai X; Shao Q; Tang J; Li X; Shu Y
    Front Oncol; 2022; 12():909035. PubMed ID: 35712486
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and Efficacy of Apatinib Monotherapy for Unresectable, Metastatic Esophageal Cancer: A Single-Arm, Open-Label, Phase II Study.
    Yanwei L; Feng H; Ren P; Yue J; Zhang W; Tang P; Shang X; Pang Q; Liu D; Chen C; Pan Z; Tao YZ
    Oncologist; 2020 Oct; 25(10):e1464-e1472. PubMed ID: 32342599
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma.
    Hsu CH; Yang TS; Hsu C; Toh HC; Epstein RJ; Hsiao LT; Chen PJ; Lin ZZ; Chao TY; Cheng AL
    Br J Cancer; 2010 Mar; 102(6):981-6. PubMed ID: 20160718
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study.
    Ma X; Li L; Zhang L; Fu X; Li X; Wang X; Wu J; Sun Z; Zhang X; Feng X; Chang Y; Zhou Z; Nan F; Zhang J; Li Z; Zhang M
    Drug Des Devel Ther; 2020; 14():275-284. PubMed ID: 32158186
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study.
    Gou M; Zhang Y; Wang Z; Qian N; Dai G
    Invest New Drugs; 2024 Apr; 42(2):171-178. PubMed ID: 38347177
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: a single-arm, open-label, prospective, multicenter study.
    Zhang Y; Xu J; Wang Q; Ling G; Mao Y; Cai M; Yang Y; Mei J; Han Z; Feng J; Wu Y; Shi L; Wen S; Shen B
    Ann Transl Med; 2022 Jun; 10(11):641. PubMed ID: 35813347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.